Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-0450-2022

Drug recall · February 2, 2022

Pioglitazone Tablets USP recall

Why: Superpotent and Failed Tablet/Capsule Specifications

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05

Lots / codes

Batch # PF4520028B & PF4520028A, Exp. Date 11/2022

Quantity
792 bottles
Company
Aurobindo Pharma USA Inc., East Windsor, NJ
Distribution
Nationwide in the US
Initiated
December 29, 2021 · Voluntary: Firm initiated
Classified
January 24, 2022
Reported
February 2, 2022
Ended
December 4, 2023
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Pioglitazone

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.